Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello Govoni

Showing results (111-120 of 254) with videos related to

Pageof 26
Sort By:
Clinical and Experimental Rheumatology|May 31, 2018
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic studyGiovanni Ciancio, Laura Sighinolfi, Federica Furini, et al.
Rheumatology and Immunology Research|December 5, 2022
Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT StudyNicoletta Luciano, Enrico Fusaro, Maria Chiara Ditto, et al.
Autoimmunity Reviews|July 23, 2023
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remissionRoberto Giacomelli, Roberto Caporali, Francesco Ciccia, et al.
The Journal of Rheumatology|March 23, 2002
Endothelial nitric oxide synthase gene polymorphisms in Behçet's diseaseCarlo Salvarani, Luigi Boiardi, Bruno Casali, et al.
Frontiers in Medicine|January 6, 2023
Residual inflammation in psoriatic arthritis patients in stable minimal disease activityPierluigi Macchioni, Antonio Marchesoni, Giovanni Ciancio, et al.
RMD Open|January 6, 2025
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort studySpyridon Katechis, Sofia Pitsigavdaki, Myrto Nikoloudaki, et al.
Annals of the Rheumatic Diseases|January 17, 2024
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progressionSofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, et al.
Advances in Therapy|August 13, 2014
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritidesMarcello Govoni, Alessandra Bortoluzzi, Andrea Lo Monaco, et al.
RMD Open|March 4, 2026
Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort studyMyrto Nikoloudaki, Georgios D Barmparis, Sofia Pitsigavdaki, et al.
Clinical and Experimental Rheumatology|February 16, 2019
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEAFabiola Atzeni, Piercarlo Sarzi-Puttini, Marco Sebastiani, et al.
Pageof 26

Showing results (111-120 of 254) with videos related to

Sort By:
Pageof 26
Clinical and Experimental Rheumatology|May 31, 2018
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic studyGiovanni Ciancio, Laura Sighinolfi, Federica Furini, et al.
Rheumatology and Immunology Research|December 5, 2022
Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT StudyNicoletta Luciano, Enrico Fusaro, Maria Chiara Ditto, et al.
Autoimmunity Reviews|July 23, 2023
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remissionRoberto Giacomelli, Roberto Caporali, Francesco Ciccia, et al.
The Journal of Rheumatology|March 23, 2002
Endothelial nitric oxide synthase gene polymorphisms in Behçet's diseaseCarlo Salvarani, Luigi Boiardi, Bruno Casali, et al.
Frontiers in Medicine|January 6, 2023
Residual inflammation in psoriatic arthritis patients in stable minimal disease activityPierluigi Macchioni, Antonio Marchesoni, Giovanni Ciancio, et al.
RMD Open|January 6, 2025
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort studySpyridon Katechis, Sofia Pitsigavdaki, Myrto Nikoloudaki, et al.
Annals of the Rheumatic Diseases|January 17, 2024
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progressionSofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, et al.
Advances in Therapy|August 13, 2014
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritidesMarcello Govoni, Alessandra Bortoluzzi, Andrea Lo Monaco, et al.
RMD Open|March 4, 2026
Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort studyMyrto Nikoloudaki, Georgios D Barmparis, Sofia Pitsigavdaki, et al.
Clinical and Experimental Rheumatology|February 16, 2019
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEAFabiola Atzeni, Piercarlo Sarzi-Puttini, Marco Sebastiani, et al.
Pageof 26